A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 30, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Non-small Cell Lung CancerSolid Tumor

Interventions

DRUG

BL-M09D1

Administration by intravenous infusion for a cycle of 3 weeks.

Trial Locations (1)

RECRUITING

Shanghai Chest Hospital, Shanghai

All Listed Sponsors

collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY